Can less be more? new study tests a gentler dosing schedule for advanced bladder cancer drug
NCT ID NCT05923190
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study is testing whether a less frequent dosing schedule of the drug enfortumab vedotin (EV), given alone or with pembrolizumab, can still control advanced bladder cancer. About 60 adults with locally advanced or metastatic urothelial carcinoma will receive EV on a modified schedule. The goal is to see if the reduced dosing maintains clinical benefit while potentially lowering side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- enfortumab vedotin (with or without pembrolizumab)
- What this could lead to
- If successful, this could show that a less frequent dosing schedule of enfortumab vedotin still controls advanced bladder cancer while reducing side effects.
- What could go wrong
- This is a small, early-phase pilot study with only 60 participants. The reduced schedule may not control the cancer as well as the standard schedule, and side effects remain possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fox Chase Cancer Center - Philadelphia
Philadelphia, Pennsylvania, 19111-2497, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can a Two-Drug attack shrink Hard-to-Treat bladder tumors?
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- Targeted drug hunts down cancer cells in advanced bladder cancer trial
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers